A randomized, controlled, pragmatic trial of an iPad-based, tailored messaging intervention to increase human papillomavirus vaccination among Latinos

Figures & data

Table 1. Demographic characteristics of participants.

		Arm Assignment
Participant Characteristics		Usual Care % (n)	Untailored % (n)	Tailored % (n)	All % (N)
Young Adults		34.6% (152)	35.5% (151)	33.3% (143)	34.5% (446)
Parents		65.4% (287)	64.55 (274)	66.7% (287)	65.5% (848)
TOTAL (100% column)		100% (439)	100% (425)	100% (430)	100% (1294)
Gender
Young Adults	Male	0% (0)	0% (0)	0% (0)	0% (0)
	Female	100% (152)	100% (151)	100% (143)	100% (446)
	TOTAL
Parents (Adolescent Gender)	Male	51.6% (148)	51.5% (141)	50.2% (144)	51.1% (433)
	Female	48.4% (139)	48.5% (133)	49.8% (143)	48.9% (415)
	TOTAL	100% (287)	100% (274)	1005 (287)	100% (848)
Race/Ethnicity
Young Adults	Hispanic	85.5% (130)	84.1% (127)	86.0% (123)	85.2% (380)
	White, Non-Hispanic	12.5% (19)	13.2% (20)	11.9% (17)	12.6% (56)
	Other, Non-Hispanic	2.0% (3)	2.6% (4)	2.1% (3)	2.2% (10)
	TOTAL	100% (152)	100% (151)	100% (143)	100% (446)
Parents (Adolescent Race/Ethnicity)	Hispanic	93.7% (269)	92.7% (254)	92.7% (266)	93% (789)
	White, Non-Hispanic	5.9% (17)	6.9% (19)	6.3% (18)	6.45 (54)
	Other, Non-Hispanic	0.3% (1)	0.4% (1)	1.0% (3)	0.6% (5)
	TOTAL	100% (287)	100% (274)	100% (287)	100% (848)
Age at Baseline		Median Age (MED)			Average
Young Adults		23	23	22	22
Parents (Adolescent Age)		12	12	12	12

Figure 1. CHICOS consort diagram for vaccination outcomes.

Table 2. Two way comparisons of adolescent vaccination between study arms.

Outcome	Comparison Arms	Odds Ratio, 95% CI
Young Adults
Got Any Dose of HPV During Study	Tailored vs. Usual Care	2.3 (0.6, 8.3)
	Untailored vs. Usual Care	2.4 (0.7, 8.9)
	Tailored vs. Untailored	0.9 (0.3, 2.6)
Initiated the Vaccine Series^b	Tailored vs. Usual Care	2.3 (0.6, 8.8)
	Untailored vs. Usual Care	1.00 (0.2, 4.6)
	Tailored vs. Untailored	2.3 (0.6, 8.6)
Initiated the Vaccine, Series not Completed^c	Tailored vs. Usual Care	5.8 (0.3, 112.8)
	Untailored vs. Usual Care	12.4 (0.2, 722.4)
	Tailored vs. Untailored	0.5 (0.0, 22.4)
Completed the Vaccine Series, Among All Eligible^d	Tailored vs. Usual Care	0.7 (0.1, 5.3)
	Untailored vs. Usual Care	1.7 (0.3, 8.3)
	Tailored vs. Untailored	0.4 (0.1, 2.6)
Completed the Vaccine Series Among Those Already Initiated at Study Start^e	Tailored vs. Usual Care	1.1 (0.0, 60.2)
	Untailored vs. Usual Care	9.3 (0.5, 193.9)
	Tailored vs. Untailored	0.1 (0.0, 2.4)
Completed the Vaccine Series, Among Those Who Initiated During the Study^f	Tailored vs. Usual Care	0.2 (0.0, 3.4)
	Untailored vs. Usual Care	0.1 (0.0, 4.7)
	Tailored v. Untailored	2.2 (0.0, 103.5)
Adolescents
Got Any Dose of HPV During Study	Tailored vs. Usual Care	1.05 (0.7, 1.5)
	Untailored vs. Usual Care	1.1 (0.7, 1.7)
	Tailored vs. Untailored	0.9 (0.7, 1.3)
Initiated the Vaccine Series^b	Tailored vs. Usual Care	1.2 (0.7, 2.0)
	Untailored vs. Usual Care	1.3 (0.7, 2.2)
	Tailored vs. Untailored	0.9 (0.5, 1.5)
Initiated the Vaccine, Series not Completed^c	Tailored vs. Usual Care	1.3 (0.4, 4.1)
	Untailored vs. Usual Care	2.3 (0.7, 7.3)
	Tailored vs. Untailored	0.6 (0.2, 1.8)
Completed the Vaccine Series, Among All Eligible^d	Tailored vs. Usual Care	1.2 (0.7, 2.1)
	Untailored vs. Usual Care	0.8 (0.5, 1.5)
	Tailored vs. Untailored	1.5 (0.9, 2.5)
Completed the Vaccine Series Among Those Already Initiated at Study Start^e	Tailored vs. Usual Care	1.6 (0.8, 3.2)
	Untailored vs. Usual Care	0.8 (0.4, 1.6)
	Tailored vs. Untailored	2.0 (1.1, 3.8)
Completed the Vaccine Series, Among Those Who Initiated During the Study^f	Tailored vs. Usual Care	0.7 (0.2, 2.2)
	Untailored vs. Usual Care	0.4 (0.1, 1.4)
	Tailored vs. Untailored	1.7 (0.6, 5.0)

^aP-value for the % vaccinated among the two arms denoted

^bDescribes those who had 0 doses at study enrollment and received at least one dose during the study period.

^cDescribes those who enrolled in the study with 0 doses, had enough time in the study period after the most recent dose to complete the series, but did not complete the series during the study period.

^dDescribes those who enrolled in the study with 0, 1 or 2 doses, had enough time in the study period after the most recent dose to complete the series, and completed the series during the study period.

^eDescribes those who enrolled in the study with 1 or 2 doses, had enough time in the study period after the most recent dose to complete the series, and completed the series during the study period.

^fDescribes those who enrolled in the study with 0 doses, had enough time in the study period after the most recent dose to complete the series, and completed the series during the study period.

Bolded p-values highlight significant results.